CHARLES SCHWAB INVESTMENT MANAGEMENT INC
Position in ANTX — AN2 Therapeutics, Inc.
CIK 884546
SAN FRANCISCO, CA
Position in ANTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$310,824
+$15,731 QoQ
Shares Held
64,220
+114.8% QoQ
Ownership
0.170%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#33
of 66 holders
Holding Since
Jun 2022
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $7,346,663,053 across 299 Biotechnology names. ANTX ranks #276 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,041,282 | $1,013,966,007 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
846,306 | $527,705,642 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
1,917,025 | $359,020,441 | |
| 4 | MRNA |
Moderna, Inc.
|
4,838,884 | $338,867,045 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
755,377 | $227,391,137 | |
| 6 | INCY |
Incyte Corp
|
1,692,439 | $191,854,884 | |
| 7 | RPRX |
Royalty Pharma plc
|
3,083,528 | $172,893,414 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,565,781 | $133,388,883 |
All Filings in ANTX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $310,824 | 64,220 | Shares | Sole | 2026-08-14 | |
| 2023-03-31 | $295,093 | 29,898 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $237,277 | 24,898 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $177,084 | 10,189 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $78,964 | 10,189 | Shares | Sole | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||